As­traZeneca gives up on late-stage IL-23 drug due to tri­al de­lays, com­pet­i­tive land­scape

As­traZeneca is shelv­ing an IL-23 an­ti­body that’s been through a wind­ing jour­ney around phar­ma — in­clud­ing stops at Am­gen and Al­ler­gan — and putting an end to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER